These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17396081)

  • 1. [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
    Lotersztajn S; Teixeira-Clerc F; Hezode C; Tran van Nhieu J; Deveaux V; Mallat A
    Gastroenterol Clin Biol; 2007 Mar; 31(3):255-8. PubMed ID: 17396081
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
    Immenschuh S
    Cardiovasc Res; 2009 Dec; 84(3):341-2. PubMed ID: 19819883
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis.
    Pandey R; Hegde VL; Singh NP; Hofseth L; Singh U; Ray S; Nagarkatti M; Nagarkatti PS
    Vitam Horm; 2009; 81():487-504. PubMed ID: 19647124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
    [No Abstract]   [Full Text] [Related]  

  • 13. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
    Patti ME
    J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of allergic contact dermatitis through the endocannabinoid system.
    Karsak M; Gaffal E; Date R; Wang-Eckhardt L; Rehnelt J; Petrosino S; Starowicz K; Steuder R; Schlicker E; Cravatt B; Mechoulam R; Buettner R; Werner S; Di Marzo V; Tüting T; Zimmer A
    Science; 2007 Jun; 316(5830):1494-7. PubMed ID: 17556587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 17. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions.
    Darmani NA
    Methods Mol Med; 2006; 123():169-89. PubMed ID: 16506408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoids and liver disease--review.
    Gabbay E; Avraham Y; Ilan Y; Israeli E; Berry EM
    Liver Int; 2005 Oct; 25(5):921-6. PubMed ID: 16162147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.